AltruBio secures $225m for immune checkpoint programme development

2024-05-22

临床2期免疫疗法

AltruBio secures $225m for immune checkpoint programme development

Preview

来源: Pharmaceutical Technology

ALTB-268 is being analysed in a Phase IIa exploratory biomarker study targeting patients with ulcerative colitis. Credit: Jo Panuwat D / Shutterstock.com.

AltruBio has secured $225m in an oversubscribed Series B financing round to progress the clinical development of its new immune checkpoint enhancer (ICE) programme.

BVF Partners led the funding round with contributions from new investors including RA Capital Management, Soleus Capital, Cormorant Asset Management and Delos Capital.

Existing investors aMoon Fund and Blackstone Multi-Asset Investing also participated in the funding syndicate.

The funds will primarily support ongoing and planned Phase II clinical studies of the ICE PSGL-1 agonist PSGL-1 agonist antibody ALTB-268 to treat ulcerative colitis (UC).

ALTB-268 is currently under investigation in a Phase IIa exploratory biomarker study targeting patients with biologic refractory UC.

See Also:Sanofi enters partnership to enhance drug development using AI

Preview

来源: Pharmaceutical Technology

Roche’s PI3K inhibitor secures breakthrough status in breast cancer

Preview

来源: Pharmaceutical Technology

The study’s primary endpoint is clinical remission per the modified Mayo score, with results expected in the first half of 2025.

AltruBio is preparing to launch a randomised, global, placebo-controlled Phase IIb clinical trial.

Clinical remission in advanced therapy-experienced as well as treatment-naïve patients with moderately to severely active UC will be the trial’s primary endpoint.

Results from the trial are anticipated in the second half of 2026.

AltruBio president and CEO Dr Judy Chou stated: “We are honoured to welcome this esteemed new group of investors, whose participation complements the support of our existing world-class investor group. Their collective backing not only affirms the potential of our programme and company but also our mission of developing durable biologic therapies for patients suffering from autoimmune diseases.

“With this substantial investment, we are one step closer to bringing our first-in-class, novel immune checkpoint enhancer, ALTB-268, through our ongoing Phase IIa exploratory biomarker study and initiating an additional Phase IIb study, while paving the way for potential indication expansion beyond ulcerative colitis.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构